- ISSN 1672-5069
- CN 34-1270/R
- CODEN SGZHBF
Journal of Practical Hepatology ›› 2025, Vol. 28 ›› Issue (2): 169-172.doi: 10.3969/j.issn.1672-5069.2025.02.003
Previous Articles Next Articles
Zhu Tingting, Chen Yiyun, Xie Fanci, et al
Received:2024-09-30
Online:2025-03-10
Published:2025-03-11
Zhu Tingting, Chen Yiyun, Xie Fanci, et al. Non-invasive assessment of liver fibrosis reverse in patients with chronic liver diseases[J]. Journal of Practical Hepatology, 2025, 28(2): 169-172.
| [1] Maeso-Díaz R, Gracia-Sancho J. Aging andchronic liver disease. Semin Liver Dis, 2020,40(4):373-384. [2] Buob S, Johnston AN, Webster CR. Portal hypertension: pathophysiology, diagnosis, and treatment. J Vet Intern Med, 2011,25(2):169-186. [3] Franchis R. Expanding consensus in portal hypertension:report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015,63(3):743-752. [4] Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology, 2009,49(3):1017-1044. [5] 刘天会.肝纤维化和肝硬化逆转的血清学评价.临床肝胆病杂志,2019,35(4):714-719. [6] Karsdal MA, Hjuler ST, Luo Y, et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. Am J Physiol Gastrointest Liver Physiol, 2019,316(1):G25-31. [7] Ito K, Murotani K, Nakade Y, et al. SerumWisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis. J Gastroenterol Hepatol, 2017,32(12):1922-1930. [8] Umemura T, Joshita S, Sekiguchi T, et al. Serum Wisteria floribundaagglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol, 2015,110(6):857-864. [9] Nielsen MJ, Karsdal MA, Kazankov K, et al. Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. Aliment Pharmacol Ther, 2016,44(11-12):1242-1252. [10] Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol, 2016,64(4):773-780. [11] Li Q, Chen L, Zhou Y. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy. Clin Exp Med, 2018,18(2):273-282. [12] Stasi C, Salomoni E, Arena U, et al. Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment:a preliminary study, Eur J Pharmacol, 2017,806(7):105-109. [13] Poynard T, McHutchison J, Manns M,et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology, 2003,38(2):481-492. [14] Tanwar S, Trembling PM, Hogan BJ, et al. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. Eur J Gastroenterol Hepatol, 2017,29(3):289-296. [15] D'Ambrosio R, Degasperi E, Aghemo A, et al. Serologicaltests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon. PLoS One, 2016,11(6):e0155967. [16] Smith AD, Porter KK, Elkassem AA,et al. Current imaging techniques for noninvasive staging of hepatic fibrosis. AJR, 2019,213(1):77-89. [17] 陈永鹏, 梁携儿. 肝纤维化和肝硬化逆转的影像学评价. 临床肝胆病杂志, 2019,35(4):720-723. [18] Horowitz JM, Venkatesh SK, Ehman RL, et al. Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. Abdom Radiol (NY), 2017,42(8):2037-2053. [19] Tang A, Cloutier G, Szeverenyi NM,et al. Ultrasound elastography and MR elastography for assessing liver fibrosis: part 1, principles and techniques. AJR, 2015,205(1):22-32. [20] Barr RG, Ferraioli G, Palmeri ML, et al. Elastographyassessment of liver fibrosis: society of radiologists in ultrasound consensus conference statement. Ultrasound Q, 2016,32(2):94-107. [21] Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut, 2007,56(7):968-973. [22] Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int, 2013,7(2):356-368. [23] 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版). 中华肝脏病杂志, 2019,27(3):10. [24] Enomoto M, Mori M, Ogawa T, et al. Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B:regression of liver stiffness during entecavir therapy. Hepatol Res, 2010,40(9):853-861. [25] Kim SU, Park JY, Kim DY, et al. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int, 2010,4(4):673-680. [26] Ogawa E, Furusyo N, Murata M, et al. Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatol Res, 2011,41(12):1178-1188. [27] Fung J, Lai CL, Cheng C, et al. Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B. Am J Gastroenterol, 2011,106(3):492-496. [28] Yan LB, Zhu X, Bai L, et al. Impact of mild to moderate elevations of alanine aminotransferase on liver stiffness measurement in chronic hepatitis B patients during antiviral therapy. Hepatol Res, 2013,43(2):185-191. [29] GL W, VW W, PC C, et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther, 2011,16(2):165-172. [30] Liang X, Xie Q, Tan D, et al. Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy:a 2-year prospective study. J Viral Hepat, 2018,25(3):296-305. [31] Zeng J, Cai S, Liu J, et al. Dynamic changes in liver stiffness measured by transient elastography predict clinical outcomes among patients with chronic hepatitis B. J Ultrasound Med, 2017,36(2):261-268. [32] Sun J, Li Y, Sun X,et al. Dynamic changes of the aspartate aminotransferase-to-platelet ratio and transient elastography in predicting a histologic response in patients with chronic hepatitis B after entecavir treatment. J Ultrasound Med, 2019,38(6):1441-1448. [33] Dong XQ, Wu Z, Li J,et al. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: a 78-week prospective study. J Gastroenterol Hepatol, 2019,34(4):755-763. [34] Kong Y, Sun Y, Zhou J,et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. J Viral Hepat, 2019,26(5):576-585. [35] Ji D, Chen Y, Shang Q, et al. Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B. Am J Gastroenterol, 2021,116(8):1676-1685. [36] Li Z, Zhu T, Zhao Z, et al. Changing liver stiffness predict regression in advanced fibrosis patients with chronic hepatitis B, but not in moderate fibrosis patients. Gastroenterol Hepatol Res, 2023,5(1):13-18. [37] Xu W, Hu Q, Chen C,et al. Non-invasive assessment of liver fibrosis regression in patients with chronic hepatitis B: a retrospective cohort study. Infect Dis Ther, 2023,12(2):487-498. [38] Apichet S, Paweenuch S. Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment. Medicine (Baltimore), 2024, 103(19):e38096. [39] Hariklia K, Konstantinos Z, Theodora O,et al. Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. a retrospective - prospective multicenter study. BMC Gastroenterol, 2024,24(1):133. [40] EASL-ALEHclinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol,2015,63(1):237-264. [41] Archer AJ, Belfield KJ, Orr JG,et al. EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis. Frontline Gastroenterol, 2022,13(5):436-439. [42] Branchi F, Conti CB, Baccarin A, et al. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol, 2014,20(40):14568-14580. [43] Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology, 2010,52(3):886-893. [44] Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int, 2015,35 (Suppl 1):78-81. [45] Li ZB, Li L, Niu XX, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int, 2021,41(6):1254-1264. [46] Yijun M, Cheng P, Huijun C,et al. Prognostic value of liver stiffness in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Rev Esp Enferm Dig, 2024,116(8):416-422. [47] Yin M, Venkatesh SK. Ultrasound or MR elastography of liver: which one shall I use? Abdom Radiol (NY), 2018,43(7):1546-1551. [48] Venkatesh SK, Talwalkar JA. When and how to use magnetic resonance elastography for patients with liver disease in clinical practice. Am J Gastroenterol, 2018,113(7):923-926. [49] Guo Y, Parthasarathy S, Goyal P,et al. Magnetic resonance elastography and acoustic radiation force impulse for staging hepatic fibrosis: a meta-analysis. Abdom Imaging, 2015,40(4):818-834. [50] Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 2005,128(2):343-350. [51] Gheorghe G, Bungău S, Ceobanu G, et al. The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc, 2021,120(2):794-803. [52] Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol, 2015,13(3):440-451,e6. [53] Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep, 2020,2(2):100067. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
